Imagine being able to spot a fire before the first flame appears by detecting smoke. This project does that for diabetes in children by finding specific markers in the blood years before they get sick. By catching it early, doctors can start treatments that prevent the most dangerous symptoms and make the disease easier to manage.
Current T1D diagnosis happens only after symptoms appear, often leading to severe complications like ketoacidosis. There is no unified European system to catch the disease in its pre-clinical stage.
A harmonized screening platform for autoantibodies and a set of SMART clinical trial designs for testing new therapies.
If you are a diagnostic company dealing with low demand for pediatric screening — this project developed a validated set of autoantibody biomarkers that allows for the screening of 200,000 children. This creates a massive new market for early-stage testing kits.
If you are a sensor company dealing with a lack of clinical data for pre-clinical patients — this project uses metabolic sensors to track disease progression. This provides the data needed to refine monitoring schedules and improve device accuracy for early-stage users.
If you are a pharma company dealing with high failure rates in clinical trials — this project developed SMART trial designs and personalized risk trajectories. This allows you to target the right patients at the right time, speeding up the approval of disease-modifying therapies.
Based on available project data, the specific cost per test is not listed, but the project is supported by an EU contribution of EUR 10,744,280.
Yes, the project is designed for large-scale application, aiming to screen 200,000 children across 14 different countries.
Based on available project data, the project focuses on validating biomarkers and creating a roadmap for therapies, which typically leads to patentable diagnostic methods or licensed screening protocols.
The project includes regulatory bodies and assesses the economic and medical impact across diverse European health systems to ensure compliance.
The project runs from 2023-11-01 to 2028-10-31, with initial screening already active in 8 sites during the first year.
The consortium is heavily weighted toward commercial application, with 15 industry partners (44% of the total 34 partners), including 4 SMEs. This high industry ratio, combined with a footprint across 14 countries, suggests a strong focus on market translation and scalability rather than purely academic research.
Contact the Katholieke Universiteit Leuven research office regarding T1D screening protocols.
Contact us to identify specific biomarker licensing opportunities from the EDENT1FI consortium.
